Making an Impact in Advanced HCC - prIME Oncology
Clinical Spotlight
Clinical Spotlight

Making an Impact in Advanced HCC

Not a member of My prIME? Join now for instant access.

Keep up to date with the latest findings in therapy for hepatocellular carcinoma (HCC) from the 2017 annual liver cancer conference in Seoul. This online activity provides an overview of key data from the conference, as well as how these findings fit into the current and evolving standard of care for advanced liver cancer.

Interactive Presentation

Interactive Presentation

Downloadable Slides

Downloadable Slides



0.5 AMA PRA Category 1 Credits



Release Date

Release Date

Sep 19, 2017

Expiration Date

Sep 19, 2018

Abstract #O-031: Updated overall survival (OS) analysis from the international, phase 3, randomized, placebo-controlled RESORCE trial of regorafenib for patients with hepatocellular carcinoma (HCC) who progressed on sorafenib treatment

Abstract #P-008: Integrated safety analysis from four phase 3 trials of regorafenib (Reg)

Abstract #P-036: Integrated safety analysis from seven sorafenib (SOR) trials in patients with hepatocellular carcinoma

Abstract #P-034: Deterioration of liver function after transarterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): An exploratory analysis of OPTIMIS, an international observational study assessing the use of sorafenib after TACE

Abstract #P-056: Weak correlation of overall survival (OS) and response rate (RR) by RECIST in advanced hepatocellular carcinoma (HCC)

Abstract #O-030: Nivolumab in sorafenib-naïve and -experienced patients with advanced hepatocellular carcinoma: CheckMate 040 study

Abstract #O-001: Phase 3 trial of lenvatinib (LEN) vs sorafenib (SOR) in first-line treatment of patients with unresectable hepatocellular carcinoma (UHCC)

Featured Experts

  • Jordi Bruix, MD, PhDUniversity of Barcelona
    Barcelona, Spain
  • Peter R. Galle, MD, PhDUniversity Medical Center Mainz
    Mainz, Germany

After successful completion of this educational activity, participants should be able to:

  • Evaluate emerging clinical trial data in HCC, including studies focused on the safety and efficacy of novel targeted therapies
  • Select patients who may benefit from emerging therapies in HCC

This educational activity is supported by a grant from Bayer HealthCare Pharmaceuticals.

Continuing Education

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Making an Impact in Advanced HCC - prIME Oncology

prIME Oncology designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


This activity is provided by prIME Oncology.

Disclosure Information

Method of Participation

There are no fees for participating in and receiving CME credit for this activity. In order to receive credit, participants must successfully complete the online posttest and activity evaluation. Your participation in this CME activity will be recorded in prIME Oncology’s database. However, upon request, your CME credit certificate will be emailed to you. Technical requirements may be found under the Terms of Use.

Links to the posttest are available on the video player pages.

In order to receive credit, participants must successfully complete the online posttest with 75% or higher.

Disclosure of Relevant Financial Relationships

prIME Oncology assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Dr Bruix has disclosed that he has received consulting fees from Abbott, Arqule, Bayer, Bristol-Myers Squibb, BTG, Daichi, GlaxoSmithKline, Kowa, Lilly, Novartis, and Roche. He has also received honoraria for promotional speaker’s bureaus and has received fees for speaking and teaching from Bayer, BTG, and Sirtex. Furthermore, he worked as an independent contractor for Arqule, Bayer, and Daichi. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Galle has disclosed that he has received consultation fees from AstraZeneca, Bayer, BMS, MSD, Lilly, Sillajen, and Sirtex. He also performed contracted research for Bayer. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

The employees of prIME Oncology have disclosed:

  • Zach Hartman, PhD (scientific content reviewer/planner) – Ownership interest in Advaxis, Inc
  • Christi Gray (editorial content reviewer) – no relevant financial relationships


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.